Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Why Morningstar thinks Anthropic is worth $1.7 trillion
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,273.30 | 109.90 | 1.20% |
| CAC 40 | 8,233.30 | 94.30 | 1.16% |
| DAX 40 | 26,267.19 | 446.83 | 1.73% |
| Dow JONES (US) | 52,389.75 | 1,104.02 | 2.15% |
| FTSE 100 | 10,782.87 | 108.93 | 1.02% |
| HKSE | 24,523.08 | 74.13 | 0.30% |
| NASDAQ | 25,253.14 | 673.71 | 2.74% |
| Nikkei 225 | 60,514.91 | 1,739.41 | 2.96% |
| NZX 50 Index | 14,108.94 | 135.32 | 0.97% |
| S&P 500 | 7,549.94 | 173.08 | 2.35% |
| S&P/ASX 200 | 9,136.40 | 106.70 | 1.18% |
| SSE Composite Index | 3,671.93 | 11.14 | 0.30% |